ITRM
Iterum Therapeutics plcCompany Information
- Company Name
- Iterum Therapeutics plc
- CIK
- CIK0001659323
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- ITRM: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- ITRM
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-11-18
- Last sale
- 2022-12-02
- Shares purchased (TTM)
- 21,000
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2025-12-31
- Institutional shares owned
- 1,407,303
- Shares outstanding
- 45,801,927
- Ownership
- 3.07%
Earnings Market Reaction
- Filing date
- 2025-11-14
- Price on filing date
- —
- 1-month reaction
- 0.40%
- 3-month reaction
- -34.69%
Balance Sheet
Values in millions ($)| Line item | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 11 | 13 | 13 | 24 | 13 | 5 | 7 | 6 | 5 | 14 | 17 | 21 | ||||||
| Short Term Investments | - | - | - | 0 | 1 | 7 | 11 | 18 | 31 | 31 | 35 | 40 | ||||||
| Accounts Receivable Net Current | 0 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Inventory Net | 1 | 1 | 1 | - | - | - | - | - | - | - | - | - | ||||||
| Income Taxes Receivable | 0 | 0 | 0 | 0 | 0 | 0 | - | 0 | - | 0 | 0 | 0 | ||||||
| Prepaid Expense And Other Assets Current | 1 | 1 | 0 | 1 | 1 | 2 | 1 | 2 | 3 | 3 | 2 | 1 | ||||||
| Assets Current | 14 | 15 | 14 | 25 | 16 | 14 | 19 | 26 | 39 | 48 | 54 | 62 | ||||||
| Intangible Assets Net Excluding Goodwill | 19 | 19 | 19 | 20 | - | - | - | - | 0 | 1 | 1 | 2 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Restricted Cash And Cash Equivalents Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 2 | 3 | ||||||
| Assets | 33 | 34 | 33 | 45 | 16 | 14 | 20 | 26 | 40 | 51 | 58 | 67 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 1 | 1 | 0 | 0 | 1 | 1 | 3 | 5 | 6 | 4 | 2 | 3 | ||||||
| Accrued Liabilities Current | 5 | 4 | 3 | 3 | 3 | 2 | 2 | 8 | 9 | 5 | 4 | 4 | ||||||
| Derivative Liabilities Current | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | ||||||
| Convertible Debt Current | 0 | 0 | 0 | 14 | 14 | 13 | 12 | - | - | - | - | - | ||||||
| Taxes Payable Current | 0 | 0 | 0 | - | - | - | 0 | - | 0 | - | - | - | ||||||
| Other Liabilities Current | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | ||||||
| Liabilities Current | 6 | 6 | 4 | 18 | 19 | 17 | 18 | 14 | 16 | 11 | 8 | 9 | ||||||
| Convertible Debt Noncurrent | - | - | - | - | - | - | - | 11 | - | - | - | - | ||||||
| Long Term Debt Noncurrent | - | - | - | - | - | - | - | 11 | 12 | 12 | 11 | 10 | ||||||
| Other Liabilities Noncurrent | - | - | - | 0 | - | 0 | 0 | 0 | 0 | 1 | 1 | 1 | ||||||
| Liabilities | 40 | 38 | 36 | 49 | 27 | 25 | 26 | 33 | 36 | 44 | 39 | 39 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 499 | 493 | 488 | 482 | 468 | 462 | 462 | 455 | 452 | 452 | 452 | 451 | ||||||
| Retained Earnings Accumulated Deficit | -506 | -497 | -491 | -486 | -479 | -473 | -468 | -461 | -449 | -445 | -433 | -423 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | - | 0 | 0 | 0 | 0 | -0 | - | 0 | 0 | -0 | -0 | -0 | ||||||
| Stockholders Equity | -7 | -4 | -3 | -4 | -12 | -11 | -6 | -6 | 3 | 7 | 19 | 28 | ||||||
| Liabilities And Stockholders Equity | 33 | 34 | 33 | 45 | 16 | 14 | 20 | 26 | 40 | 51 | 58 | 67 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | ||||||
| Preferred Stock Shares Authorized | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | ||||||
| Common Stock Shares Authorized | 80 | 80 | 80 | 80 | 80 | 80 | 80 | 80 | 80 | 80 | 20 | 20 | ||||||
| Common Stock Shares Issued | 49 | 42 | 36 | 32 | 23 | 17 | 16 | 13 | 13 | 13 | 13 | 13 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialIterum Therapeutics plc (ITRM) — SEC Financial Statements & Analysis
Iterum Therapeutics plc (ITRM) is a pharmaceutical preparations company, incorporated in L2. Iterum Therapeutics plc trades on Nasdaq as: ITRM. Iterum Therapeutics plc (ITRM)'s most recent SEC filing is a Form 10-Q for the period ended 2025-09-30, filed with the SEC on 2025-11-14. Based on that filing, On profitability, Iterum Therapeutics plc posts an operating margin of -5292.31%, a net margin of -6913.08%, a Return on Equity (ROE) of 285.48%, a Return on Assets (ROA) of -111.35%, and a Return on Invested Capital (ROIC) of -266.00%. Per share, it reports EPS of $-0.59, diluted EPS of $-0.59, free cash flow per share of $-0.43, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of -11.76% year-over-year and EPS growth of -61.38% year-over-year. On the balance sheet, it maintains a current ratio of 2.13x, a quick ratio of 1.78x, working capital of $7.30M, a debt-to-equity ratio of -5.40x, a debt ratio of 1.23, an interest coverage ratio of -20.12x, free cash flow of $-19.53M (TTM), and net debt of $-11.00M. Figures sourced from SEC EDGAR.
- EPS TTM
- $-0.59
- ROE TTM
- 285.48%
- ROA TTM
- -111.35%
- Debt To Equity
- -5.40x
- Free Cash Flow TTM
- $-19.53M
Data as of 2025-09-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Iterum Therapeutics plc in?
Iterum Therapeutics plc (ITRM) operates in the Pharmaceutical Preparations industry.
What exchange does ITRM trade on?
Iterum Therapeutics plc (ITRM) trades on the Nasdaq.
Where is Iterum Therapeutics plc incorporated?
Iterum Therapeutics plc is incorporated in Ireland.
When was Iterum Therapeutics plc (ITRM)'s most recent SEC filing?
Iterum Therapeutics plc (ITRM)'s most recent SEC filing is a Form 10-Q for the period ended 2025-09-30, filed with the SEC on 2025-11-14.
What is ITRM's EPS (earnings per share)?
Iterum Therapeutics plc (ITRM)'s trailing twelve month EPS is $-0.59 as of 2025-09-30.
What is ITRM's ROE (return on equity)?
Iterum Therapeutics plc (ITRM)'s trailing twelve month Return on Equity (ROE) is 285.48% as of 2025-09-30.
What is ITRM's ROA (return on assets)?
Iterum Therapeutics plc (ITRM)'s trailing twelve month Return on Assets (ROA) is -111.35% as of 2025-09-30.
What is ITRM's ROIC (return on invested capital)?
Iterum Therapeutics plc (ITRM)'s trailing twelve month Return on Invested Capital (ROIC) is -266.00% as of 2023-09-30.